+ Watch LDR
on My Watchlist
The Company is a provider of analytical services to determine occupational and environmental radiation exposure.
For reference point and to allow for comments by others. As of the end of March, 2013.ROE 21.91%Trailing PE 29.35PB 6.58Div yield 4.20%
LDR is small cap and tends to trade in a channel. It has low debt. One day it will be discovered by Wall Street.
it's all in how you play the game
The expansion of the nuclear sector is both in medicine and energy and is not confined the the United States. South America, Europe, Asia, and the Middle East are all expanding nuclear capabilities and research. Landauer is poised to take advantage of both with their trusted service. This company is staying focused on what they do well and are quietly cashing in as they perform.
Dividend yield is very good, steady solid growth in past years, should not be effected as much by the recession and should recover very well.
In daily and weekly uptrend, trading above 9 and 18 day average. If all time high of 74.51 is broken, LDR should trade at 82.80 by March 2 for a 14% gain. Buy at 72.50 with a stop at 69.8
Bullish signal ;)
This pick is finally on the positive side for me. Like has been stated by others, this one is not sexy, but will stay solid. Great div makes this a great play in a tought market (like the current one).
Except for government installations, this company has the lock on radiation dosimetry (radiation exposure per person) in the US, Japan, Brazil. It has the low cost proprietary methodology. Every person who works in a medical facility who receives any radiation exposure will be seen wearing a Landauer badge. It signs new contracts yearly; the quarter to quarter earnings are pretty much level over the year. It has little debt. Its sideline is its radon measuring kits in home sales. It has competitors here and we know where home sales are now, but this represents a piddling part of LDR's income stream. This is a steady eddie dividend stock. Some recent shortfalls in quarterly earnings were attributed to overhauling internal information systems, which should enhance margins going forward. This is a BORING stock. Nonetheless, I've owned it for 15 years and have been unable to sell it, when I look at its year to year performance vs other more exciting stocks in my portfolio. LDR increases its dividend yearly, like clockwork. Until doctors quilt ordering CT scans and xrays or until a new, cheaper, superior technology hits the marketplace, this company will thrive. Heck, buy this one for your mother-in-law.
Good dividend low debt. They could be a little high right now but longer term looks attractive.
This is a speculative play for the long term. I think that its exposure the field of radiation monitoring will give it ample room to grow with possiblities in the medical, security and energy fields. All of these sectors will be strong in the upcoming future.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions